MEI Pharma reports $20.5M cash; strategic alternatives review ongoing

Lite Strategy, Inc.

Cash and cash equivalents $20.5M as of March 31, 2025, with no outstanding debt.
Strategic alternatives review continues since July 2024; Oppenheimer & Co. serving as exclusive financial advisor.
Reduction-in-force progressing in stages as operational and strategic direction evolves.
No assurance any transaction will result; updates only if completed or legally required.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.